Knight Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA4990531069
CAD
6.05
0.01 (0.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Knight Therapeutics, Inc. stock-summary
stock-summary
Knight Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.
Company Coordinates stock-summary
Company Details
3400 De Maisonneuve Blvd W , MONTREAL QC : H3Z 3B8
stock-summary
Tel: 1 514 4844483
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.15%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. James Gale
Independent Chairman of the Board
Ms. Samira Sakhia
President, Director
Mr. Jonathan Goodman
Chief Executive Officer, Director
Mr. Robert Lande
Independent Director
Ms. Janice Murray
Independent Director
Mr. Nicolas Sujoy
Independent Director
Mr. Michael Tremblay
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
107 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 581 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

-0.11%

stock-summary
Price to Book

0.76